Firefly Neuroscience opened lower at $1.01, compared with its previous close of $1.04. In the last trading session, the stock traded between $0.97 and $1.01. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 3 years ago in Firefly Neuroscience is now worth
$ 11.29
Resulting in a loss of
$ 88.71 (88.71%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
No analyst rating data available.
Markets Today
Today's Change
$-0.09 (-8.37%)
Day High
$1.01
Day Low
$0.97
Day Open
$1.01
Prev Close
$1.04
Volume
38,325
1W Return
-6.93%
1M Return
-14.68%
3M Return
-16.77%
6M Return
-47.06%
1Y Return
-42.24%
Fundamentals
Market Cap ($ Mn)
15
PE Ratio
-
PB Ratio
1.16
PEG Ratio
-
ROE
-290.64%
ROCE
-288.74%
EPS (TTM)
-
Investment Returns
1 Week
-6.93%
1 Month
-14.68%
3 Months
-16.77%
6 Months
-47.06%
9 Months
20.18%
Financials
Quarterly
All values in $ Mn
0.3
Jun 25
0.4
Sep 25
0.4
Dec 25
0.5
Mar 26
0.5
Jun 26
0.6
Sep 26
Updates
25Sep
Firefly shares jump 42% on NeuroSigma pediatric ADHD partnership
Firefly Neuroscience shares surged 42.01% to $1.68 following the partnership announcement. Collaboration integrates Firefly's AI-powered Evoke platform with NeuroSigma's Monarch eTNS System. Targets the ~2.1 million children with ADHD who currently receive no specific treatment. Monarch eTNS is the first FDA-cleared non-drug monotherapy for pediatric ADHD ages 7-12.
1mo ago
17Sep
Firefly Neuroscience signs deal to integrate AI platform with Radial
Firefly Neuroscience (NASDAQ: AIFF) partners with Radial to integrate FDA 510(k)-cleared Evoke platform into RadialOS. Integration aims to add objective brain function measures to diagnostic workflows across Radial's 27 clinics. Radial operates the largest US brain medicine clinic network with over 100 clinicians. Deal follows Radial's August 2026 acquisition of Mindful Health Solutions management services.
1mo ago
28Jul
Firefly Neuroscience partners with Next Health for precision cognitive health platform
Firefly Neuroscience and Next Health announced a strategic partnership on July 28, 2026, to launch a precision cognitive health platform. The initiative integrates Firefly’s FDA-cleared EEG/ERP brain biomarker technology with Next Health’s personalized cognitive peptide protocols, aiming to provide objective measures of brain function for physicians. This collaboration follows an FDA Advisory Committee recommendation to add six therapeutic peptides, including Epitalon and Semax, to the list of substances eligible for pharmacy compounding, potentially broadening access to these emerging therapies.
